respiratory therapist program
BIOLASE Technology, Inc. (NASDAQ: BLTI), the worlds leading dental laser company, announced today that it has amended its licensing and distribution agreement with Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners. Within the United Kingdom, Australia, New Zealand, Belgium, Luxembourg, Netherlands, Spain, Germany, Italy, Austria, and North America, all dental sales will continue to be provided exclusively through Henry Schein.
The amended agreement provides strong incentives for Henry Schein to focus on its core customer base, and the purchase minimums have been agreed based upon that focus. In addition to the Henry Schein core customer base, BIOLASE will have strong incremental sales and margin incentives to penetrate additional dental offices. The agreement also allows for higher sales organization incentives, unique financing programs and increased luminary and educational events.
The new purchasing arrangement provides for minimum purchase commitments for laser equipment totaling $18 million over a twelve-month term, plus a large portion of additional laser equipment sales generated by BIOLASEs increased focus into the additional accounts not traditionally focused on by Henry Schein. In addition, Henry Schein will purchase other categories of products, such as consumables, parts, and services as needed, without any minimum or cap. For perspective, the total non-laser revenues of BIOLASE for 2009 were $11.6 million. Under the previous agreement, minimum purchase commitments totaling $42.7 million for all laser equipment, products, and services in all applicable markets through the fourteen-month period ending March 31, 2010 will be satisfied.
BIOLASE CEO David Mulder said, “Since partnering with Henry Schein in 2006, our sales of diode lasers, consumables, and services have more than doubled, and we have enjoyed a deeper penetration into a solid base of Henry Schein accounts. We expect that penetration to continue, but are looking for additional upside by rapidly expanding Waterlase® penetration into the rest of the North American marketplace. Based upon Henry Scheins reported overall market share in North America and the incremental opportunities we are pursuing together, we anticipate strong upside. We are excited that the extended agreement will expand our reach, while maintaining the strength and support of the Henry Schein organization.”
The extended and amended agreement provides for a one-year term, and either BIOLASE or Henry Schein may request termination of the agreement upon 60 days advance written notice to the other party. The agreement may be extended by BIOLASE and Henry Schein for an additional six months, upon mutual agreement of the parties.
BOCA RATON, Fla. — Cross Country Healthcare, Inc. (Nasdaq:CCRN) announced today that it is
scheduled to make a presentation on Wednesday, March 24, 2010, at 3:15
p.m. Eastern Time at the Barclays Capital 2010 Global Healthcare
Conference being held at the Lowes Miami Beach Hotel in Miami Beach,
Florida.
In addition to historical information, this press release contains
statements relating to our future results (including certain projections
and business trends) that are “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and are subject to the “safe harbor” created by those
sections. Forward-looking statements consist of statements that are
predictive in nature, depend upon or refer to future events. Words such
as “expects”, “anticipates”, “intends”, “plans”, “believes”,
“estimates”, “suggests”, “seeks”, “will” and variations of such words
and similar expressions intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results and
performance to be materially different from any future results or
performance expressed or implied by these forward-looking statements.
These factors include, without limitation, the following: our ability to
attract and retain qualified nurses, physicians and other healthcare
personnel, costs and availability of short-term housing for our travel
nurses and physicians, demand for the healthcare services we provide,
both nationally and in the regions in which we operate, the functioning
of our information systems, the effect of existing or future government
regulation and federal and state legislative and enforcement initiatives
on our business, our clients’ ability to pay us for our services, our
ability to successfully implement our acquisition and development
strategies, the effect of liabilities and other claims asserted against
us, the effect of competition in the markets we serve, our ability to
successfully defend the Company, its subsidiaries, and its officers and
directors on the merits of any lawsuit or determine its potential
liability, if any, and other factors set forth in Item 1A. “Risk
Factors” in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2008, and our other Securities and Exchange Commission
filings made during 2009.
BIOLASE Technology, Inc. (NASDAQ: BLTI), the worlds leading dental laser company, announced today that it has amended its licensing and distribution agreement with Henry Schein, Inc. (NASDAQ: HSIC), the largest provider of healthcare products and services to office-based practitioners. Within the United Kingdom, Australia, New Zealand, Belgium, Luxembourg, Netherlands, Spain, Germany, Italy, Austria, and North America, all dental sales will continue to be provided exclusively through Henry Schein.
The amended agreement provides strong incentives for Henry Schein to focus on its core customer base, and the purchase minimums have been agreed based upon that focus. In addition to the Henry Schein core customer base, BIOLASE will have strong incremental sales and margin incentives to penetrate additional dental offices. The agreement also allows for higher sales organization incentives, unique financing programs and increased luminary and educational events.
The new purchasing arrangement provides for minimum purchase commitments for laser equipment totaling $18 million over a twelve-month term, plus a large portion of additional laser equipment sales generated by BIOLASEs increased focus into the additional accounts not traditionally focused on by Henry Schein. In addition, Henry Schein will purchase other categories of products, such as consumables, parts, and services as needed, without any minimum or cap. For perspective, the total non-laser revenues of BIOLASE for 2009 were $11.6 million. Under the previous agreement, minimum purchase commitments totaling $42.7 million for all laser equipment, products, and services in all applicable markets through the fourteen-month period ending March 31, 2010 will be satisfied.
BIOLASE CEO David Mulder said, “Since partnering with Henry Schein in 2006, our sales of diode lasers, consumables, and services have more than doubled, and we have enjoyed a deeper penetration into a solid base of Henry Schein accounts. We expect that penetration to continue, but are looking for additional upside by rapidly expanding Waterlase® penetration into the rest of the North American marketplace. Based upon Henry Scheins reported overall market share in North America and the incremental opportunities we are pursuing together, we anticipate strong upside. We are excited that the extended agreement will expand our reach, while maintaining the strength and support of the Henry Schein organization.”
The extended and amended agreement provides for a one-year term, and either BIOLASE or Henry Schein may request termination of the agreement upon 60 days advance written notice to the other party. The agreement may be extended by BIOLASE and Henry Schein for an additional six months, upon mutual agreement of the parties.
If you found this page useful, consider linking to it.
Simply copy and paste the code below into your web site (Ctrl+C to copy)
It will look like this: respiratory therapist program
Leave a Reply